Phase 1 Leukaemia Trial, Recruiting NCT07297173 Sponsor: Beijing 302 Hospital Condition: Leukaemia
Back to Leukaemia

Phase 1 Leukaemia Trial, Recruiting

NCT07297173
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 15 years or older, of any gender, race, or ethnicity.
  • People who have a confirmed diagnosis of relapsed or refractory leukemia (leukemia that has come back or stopped responding to treatment), classified according to standard international guidelines.
  • People whose liver is functioning well enough, based on specific blood test results being within acceptable ranges.
  • People whose kidneys are functioning well enough, based on specific blood test results being within acceptable ranges.
  • People whose heart is pumping normally, confirmed by an ultrasound of the heart showing a pumping strength above 50%.
  • People who have at least one available donor aged 18 or older who is a partial tissue-type (HLA) mismatch, to provide a specific type of immune cells for the first stage of treatment. If that donor cannot also serve as a stem cell transplant donor, a separate stem cell transplant donor aged 18 or older must also be available (confirm with trial site for donor matching details).
  • People (or their legal representatives) who are willing to sign a consent form confirming they understand and agree to take part.
  • The donor must also meet the trial site's health requirements for donating blood stem cells and be willing to sign their own consent form.

Who may not be able to join:

  • People with an active infection or uncontrolled bleeding that has not been brought under control.
  • People with significant heart conditions, such as serious irregular heartbeat, heart failure, a heart attack within the past 6 months, or moderate to severe heart disease based on a standard heart function scale.
  • People with an autoimmune disease that is not under control, or who require ongoing medication to suppress their immune system.
  • People with a history of a severe reaction to a blood transfusion or infusion.
  • Women who are breastfeeding, women who could become pregnant and have a positive pregnancy test, or women who could become pregnant and are not willing to use adequate contraception during the trial.
  • People with a psychiatric condition or cognitive (thinking or memory) difficulty that, in the treating doctor's judgement, would make it difficult to follow the trial requirements.
  • People who have had major surgery within the 4 weeks before enrolling in the trial.
  • People who have another life-threatening illness in addition to leukemia, or another serious uncontrolled medical condition.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bo Cai, MD, Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital

Phone: +861066947168

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Beijing 302 Hospital
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
1 December 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Graft-Versus-Host Disease (GVHD); Infections; Hematological Toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov